Posted inDermatology news Oncology
Efficacy and Tolerability of Long-Term Low-Dose Capecitabine for Refractory Cutaneous Field Cancerization: Insights from a Retrospective Cohort Study
This study demonstrates that long-term, low-dose capecitabine significantly reduces keratinocyte carcinoma surgeries in patients with refractory cutaneous field cancerization and is generally well tolerated, offering a promising therapeutic option.
